TABLE 1.
Ex vivo and in vitro analysis of neutralization activitya
| Patient | Stage | Response | IC70 (μg/ml) of:
|
Mean DPlasma (μg/ml), wk 2-12)b
|
Synergy analysis
|
NT70 of plasma against:
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JR-FL
|
Autologous virus
|
|||||||||||||
| 2G12 | 2F5 | 4E10 | 2G12 | 2F5 | 4E10 | MAb ratioc | Inx70d | Total | MAb | Total | MAb | |||
| NAB01 | C | No | >50 | 1.6 | 0.8 | 406.1 | 85.7 | 144.1 | 20:4:7 | 0.734 | 227 | 241 | 1,125 | 525 |
| NAB02 | C | No | 21.3 | 2.2 | 3.1 | 376.8 | 50.7 | 85.7 | 8:1:2 | 0.380 | 375 | 279 | 281 | 137 |
| NAB03 | C | Yes | 0.6 | 7.0 | 7.9 | 523.9 | 48.4 | 115.1 | 10:1:2.5 | 0.676 | 394 | 490 | 1,022 | 1,691 |
| NAB04 | C | Yes | 3.2 | 0.5 | 1.7 | 640.7 | 97.0 | 161.1 | 14:2:3 | 0.554 | 491 | 539 | 1,109 | 1,349 |
| NAB05 | C | No | >50 | 7.2 | 14.4 | 232.7 | 18.9 | 37.8 | 12:1:2 | 0.621 | 348 | 285 | 112 | 9 |
| NAB06 | C | No | 17.7 | 8.9 | 9.0 | 281.9 | 60.3 | 72.4 | 10:2:2.5 | 0.507 | 878 | 348 | 273 | 76 |
| NAB07 | C | No | >50 | >50 | 9.3 | 463.4 | 46.0 | 98.0 | 10:1:2 | 1.000 | 548 | 624 | 196 | 11 |
| NAB08 | A | Yes | 5.8 | 3.7 | 5.0 | 554.5 | 62.7 | 108.8 | 10:1:2 | 0.524 | 511 | 623 | 308 | 259 |
| NAB09 | C | No | >50 | 1.8 | 14.0 | 271.6 | 47.4 | 70.3 | 7:1:1.5 | 0.769 | 319 | 233 | 2,814 | 58 |
| NAB10 | A | No | >50 | 5.0 | 13.4 | 670.3 | 65.3 | 180.3 | 10:1:3 | 0.634 | 786 | 578 | 181 | 114 |
| NAB11 | A | No | 14.3 | 10.5 | 14.8 | 649.4 | 58.6 | 128.2 | 12:1:2.5 | 0.575 | 334 | 526 | 49 | 162 |
| NAB12 | A | Yes | 9.7 | >50 | 20.0 | 484.4 | 74.6 | 142.3 | 8:1:2 | 0.608 | 513 | 461 | 42 | 125 |
| NAB13e | A | Yes | >50 | 0.2 | 12.8 | 726.2 | 92.7 | 175.7 | 8:1:2 | 1.082 | 351 | 475 | 443 | 742 |
| NAB14e | A | Yes | >50 | 0.3 | 1.7 | 752.2 | 80.6 | 189.8 | 10:1:2.5 | 0.927 | 592 | 612 | 2,508 | 486 |
A, acute HIV infection; C, chronic HIV infection. Response to passive immunization was assessed as described previously (26). IC70s of MAbs against the respective pretreatment patient viruses and mean total or MAb-mediated NT70s of patient plasma samples against JR-FL or autologous viruses were measured in the TZM-bl assay system.
Mean trough dose of MAb in plasma samples of patients during weeks 2 to 12 of passive immunization (see Trkola et al. [26]).
Averaged MAb ratio (2G12:2F5:4E10) chosen for synergy analysis.
Inx at 70% inhibition, calculated as shown in Table 2. Inx70 was calculated only for MAbs with IC70s of <50 μg/ml.
Week 2 sample unavailable; analysis restricted to samples from weeks 4 to 12.